scholarly journals Parathyroid Hormone Status in Patients with End Stage Renal Disease on Maintenance Haemodialysis

2014 ◽  
Vol 4 (1) ◽  
pp. 13-17
Author(s):  
SM Sajjad ◽  
YA Zaman ◽  
MA Rahim ◽  
A Mahmuda ◽  
WMM Haque ◽  
...  
Keyword(s):  
Vitamin D ◽  
Parathyroid Hormone ◽  
Calcium Phosphate ◽  
Renal Disease ◽  
End Stage Renal Disease ◽  
Maintenance Haemodialysis ◽  
Stage Renal Disease ◽  
End Stage ◽  
Esrd Patients ◽  
Pth Level

Objective: To evaluate parathyroid hormone (PTH) status among end stage renal disease (ESRD) patients on maintenance haemodialysis (MHD). Methodology: This descriptive cross-sectional study was done in the Department of Nephrology, BIRDEM General Hospital, Dhaka, from April to September 2011. Results: A total of 50 patients were included in this study with a 3:2 male predominance. Mean age was 54.6 (range 34-76) years. Mean duration of ESRD was 3.73 years. All the patients were diabetic and other common co-morbidities were hypertension (76%), dyslipidaemia (56%), ischaemic heart disease (48%) and stroke (12%). They were receiving calcium (72%), vitamin D (40%), both calcium and vitamin D (38%) supplementation and 20% were not on any medication for treatment of chronic kidney disease mineral bone disorder (CKD-MBD). Mean pre-dialysis values of urea and creatinine were 30.28 mg/dl and 8.67 mg/dl respectively. Mean (± SD) serum level of calcium, phosphate and PTH were 8.32 (±1.26) mg/dl, 4.42 (±1.54) mg/dl and 125.45±117.71 pg/ml respectively. In 76% of the study subjects, PTH level was above normal. Significant difference (P=<0.05) in PTH levels was observed among patients with and without any medication for prevention of CKD-MBD but the levels were within the acceptable range. Serum calcium level in the study subjects had significant positive relationship with serum PTH level. It was also observed that PTH level had significant negative relationship with phosphate level. Conclusion: PTH level was higher in ESRD patients on MHD specially those who were not on any medication than those who took calcium, vitamin D or both but it was still within the acceptable reference range. In such patients, serum calcium, phosphate and PTH levels should be monitored periodically. DOI: http://dx.doi.org/10.3329/birdem.v4i1.18547 Birdem Med J 2014; 4(1): 13-17

scholarly journals Risk Estimation of Aortic Stiffness in Patients with End Stage Renal Disease on Maintenance Haemodialysis

2019 ◽  
Vol 9 (1) ◽  
pp. 59-62
Author(s):  
Muhammad Abdur Razzak ◽  
Debasish Kumar Saha ◽  
Muhammad Ehsan Jalil ◽  
Mohammad Omar Faruque Miah ◽  
Abu Noim Md Abdul Hai ◽  
...  
Keyword(s):  
Renal Disease ◽  
Serum Calcium ◽  
End Stage Renal Disease ◽  
Aortic Stiffness ◽  
Serum Phosphate ◽  
Serum Phosphate Level ◽  
Maintenance Haemodialysis ◽  
Stage Renal Disease ◽  
End Stage ◽  
Esrd Patients

Background: The stiffness of the large elastic arteries increase the morbidity and mortality. The purpose of the present study was to estimate the risk of aortic stiffness among end stage renal disease patients on maintenance haemodialysis. Methods: This cross-sectional study was carried out in the Department of Nephrology at National Institute of Kidney Diseases and Urology (NIKDU), Dhaka and National Institute of Cardiovascular Disease and Hospital (NICVD), Dhaka, Bangladesh from January 2013 to December 2014 for a period of two years. Chronic kidney disease in stage 5 [CKD-5(D)] patients older than 18 years on maintenance haemodialysis (MHD) for more than 3 months were designated as case group and age and sex matched non CKD patients were considered as control group. Serum calcium, serum albumin, serum phosphate and iPTH were estimated by semi-automated biochemistry analyzer from the Department of Biochemistry of NIKDU, Dhaka and NICVD, Dhaka. Plain Xray abdomen in lateral view was performed for all patients. Result: A total number of 100 patients were enrolled for this study of which 50 patients were in end stage renal disease (ESRD) group and the rest 50 patients were in non-CKD group. Mean (±SD) aortic stiffness index was significantly higher (P<0.001) among ESRD population (3.27±1.70) compared to non CKD group of population (2.00±0.73). Mean (±SD) serum calcium (corrected) level was significantly high (P<0.001) in ESRD patients (9.79±0.87) compared to non CKD group of population (9.13±0.70). Mean (±SD) serum phosphate level was significantly higher (P<0.001) in ESRD patients (5.71±0.96) compared to non CKD group of population (4.20±0.59). However, mean (±SD) iPTH level showed no significant difference between ESRD (25.33±51.98) and non CKD group of population (38.53±19.52). Conclusion: In conclusion, aortic stiffness is significantly higher among ESRD subjects. Birdem Med J 2019; 9(1): 59-62

scholarly journals Risk Estimation of Aortic Stiffness in Patients with End Stage Renal Disease under Maintenance Haemodialysis

2019 ◽  
Vol 14 (2) ◽  
pp. 67-70
Author(s):  
Md Rasul Amin ◽  
Abdur Razzak ◽  
GM Sadik Hasan ◽  
ANM Abdul Hai ◽  
Chayan Kumar Singho ◽  
...  
Keyword(s):  
Renal Disease ◽  
Serum Calcium ◽  
End Stage Renal Disease ◽  
Aortic Stiffness ◽  
Serum Phosphate ◽  
Serum Phosphate Level ◽  
Maintenance Haemodialysis ◽  
Stage Renal Disease ◽  
End Stage ◽  
Esrd Patients

Background: The stiffness of the large elastic arteries increase the morbidity and mortality. Objective: The purpose of the present study was to estimate the risk of aortic stiffness among end stage renal disease patients under maintenance haemodialysis. Methodology: This case-control study was carried out in the Department of Nephrology at National Institute of Kidney Diseases and Urology (NIKDU), Dhaka and National Institute of Cardiovascular Disease and Hospital (NICVD), Dhaka, Bangladesh from January 2013 to December 2014 for a period of two (02) years. Chronic kidney disease in stage 5 [CKD-5(D)] patients older than 18 years on maintenance haemodialysis (MHD) for more than 3 months were designated as case group and age and sex matched non CKD patients were considered as control group. Serum calcium, serum albumin, serum phosphate and iPTH were estimated by semi-automated biochemistry analyzer from the Department of Biochemistry of NIKDU, Dhaka and NICVD, Dhaka. Plain X-ray abdomen in lateral view was performed for all patients. Result: A total number of 100 patients were enrolled for this study of which 50 patients were in end stage renal disease (ESRD) group and the rest 50 patients were in non-CKD group. Mean (±SD) aortic stiffness index was significantly higher (P<0.001) among ESRD population (3.27±1.70) compared to non CKD group of population (2.00±0.73). Mean (±SD) serum calcium (corrected) level was significantly high (P<0.001) in ESRD patients (9.79±0.87) compared to non CKD group of population (9.13±0.70). Mean (±SD) serum phosphate level was significantly higher (P<0.001) in ESRD patients (5.71±0.96) compared to non CKD group of population (4.20±0.59). However, mean (±SD) iPTH level showed no significant difference between ESRD (25.33±51.98) and non CKD group of population (38.53±19.52). Conclusion: In conclusionaortic stiffness is significantly higher among ESRD subjects. University Heart Journal Vol. 14, No. 2, Jul 2018; 67-70

scholarly journals FVC, FEV1, FEV1/FVC ratio and FEF25-75% in End-stage renal disease (ESRD) patients undergoing maintenance haemodialysis

2013 ◽  
Vol 8 (1) ◽  
pp. 33-36
Author(s):  
Farhana Hoque ◽  
Shelina Begum ◽  
Abdul Latif ◽  
Afroza Begum ◽  
Shamima Sultana
Keyword(s):  
Renal Disease ◽  
End Stage Renal Disease ◽  
Cross Sectional Study ◽  
Pulmonary Complications ◽  
Cross Sectional ◽  
Maintenance Haemodialysis ◽  
Lung Functions ◽  
Stage Renal Disease ◽  
End Stage ◽  
Esrd Patients

Background: End-stage renal disease causes multiple pulmonary complications and lung functions are decreased in ESRD patients undergoing maintenance haemodialysis. Objectives: To observe FVC, FEV1, FEV1/FVC ratio and FEF25-75% in ESRD patients undergoing maintenance haemodialysis to evaluate their lung functions status. Methods: This cross sectional study was carried out in the Department of Physiology, BSMMU, Dhaka, from July 2011 to June 2012. For this, 30 ESRD patients aged 25-55 years undergoing maintenance haemodialysis with less than 1 year duration were studied and 30 age, sex matched healthy subjects were taken as control. Patients were selected from the Nephrology department of BSMMU, Dhaka. FVC, FEV1, FEV1/FVC ratio and FEF25-75% were measured by a Digital Spirometer. For statistical analysis Independent Sample‘t’ test and One way ANOVA test were performed as applicable. Results: The mean percentage of predicted values of FVC, FEV1 and FEF25-75% were significantly lower in patients except FEV1/FVC ratio which was almost similar to control. 63.33% patients had restrictive and 36.67% patients had both restrictive and obstructive (small airway obstruction) feature. Conclusion: This study concluded that some pulmonary functions were markedly reduced in ESRD patients undergoing maintenance haemodialysis. In addition most of the patients were suffering from restrictive and some of them were affected with both obstructive and restrictive type of pulmonary disorders. DOI: http://dx.doi.org/10.3329/jbsp.v8i1.16645 J Bangladesh Soc Physiol. 2013, June; 8(1): 33-36

scholarly journals α1-Acid Glycoprotein and Dietary Intake in End-Stage Renal Disease Patients

Nutrients ◽  
2021 ◽  
Vol 13 (11) ◽  
pp. 3671
Author(s):  
Małgorzata Maraj ◽  
Paulina Hetwer ◽  
Beata Kuśnierz-Cabala ◽  
Barbara Maziarz ◽  
Paulina Dumnicka ◽  
...  
Keyword(s):  
Vitamin D ◽  
Renal Disease ◽  
Dietary Intake ◽  
End Stage Renal Disease ◽  
Plant Protein ◽  
Maintenance Hemodialysis ◽  
Acid Glycoprotein ◽  
Stage Renal Disease ◽  
End Stage ◽  
Esrd Patients

Management of end-stage renal disease (ESRD) patients requires monitoring each of the components of malnutrition–inflammation–atherosclerosis (MIA) syndrome. Restrictive diet can negatively affect nutritional status and inflammation. An acute-phase protein—α1-acid glycoprotein (AGP), has been associated with energy metabolism in animal and human studies. The aim of our study was to look for a relationship between serum AGP concentrations, laboratory parameters, and nutrient intake in ESRD patients. The study included 59 patients treated with maintenance hemodialysis. A 24 h recall assessed dietary intake during four non-consecutive days—two days in the post-summer period, and two post-winter. Selected laboratory tests were performed: complete blood count, serum iron, total iron biding capacity (TIBC) and unsaturated iron biding capacity (UIBC), vitamin D, AGP, C-reactive protein (CRP), albumin, prealbumin, and phosphate–calcium metabolism markers (intact parathyroid hormone, calcium, phosphate). Recorded dietary intake was highly deficient. A majority of patients did not meet recommended daily requirements for energy, protein, fiber, iron, magnesium, folate, and vitamin D. AGP correlated positively with CRP (R = 0.66), platelets (R = 0.29), and negatively with iron (R = −0.27) and TIBC (R = −0.30). AGP correlated negatively with the dietary intake of plant protein (R = −0.40), potassium (R = −0.27), copper (R = −0.30), vitamin B6 (R = −0.27), and folates (R = −0.27), p < 0.05. However, in multiple regression adjusted for confounders, only CRP was significantly associated with AGP. Our results indicate that in hemodialyzed patients, serum AGP is weakly associated with dietary intake of several nutrients, including plant protein.

scholarly journals Lack of Comparability of Intact Parathyroid Hormone Measurements among Commercial Assays for End-Stage Renal Disease Patients: Implication for Treatment Decisions

2006 ◽  
Vol 52 (9) ◽  
pp. 1771-1776 ◽  
Author(s):  
Tom Cantor ◽  
Zan Yang ◽  
Nicolae Caraiani ◽  
Ekambaram Ilamathi
Keyword(s):  
Parathyroid Hormone ◽  
Renal Disease ◽  
End Stage Renal Disease ◽  
Method Comparison ◽  
Intact Parathyroid Hormone ◽  
Intact Pth ◽  
Edta Plasma ◽  
Stage Renal Disease ◽  
End Stage ◽  
Esrd Patients

Abstract Background: Variability among assays used to measure intact parathyroid hormone (iPTH) is of particular concern because of the routine use of iPTH assay results to guide management of osteodystrophy and calcium metabolism in patients with end-stage renal disease (ESRD). The aim of this study was to determine the extent to which results from commercially available iPTH assays diverge from results obtained with the Nichols Allegro® Intact PTH immunoradiometric assay (IRMA), which was used as evidence in the development of the National Kidney Foundation’s Kidney Disease Outcomes Quality Initiative Clinical Practice Guidelines. Methods: We divided EDTA plasma from 46 dialysis patients with ESRD and measured iPTH values with the following commercially available iPTH assays: Nichols’ Allegro iPTH IRMA, Nichols Advantage® iPTH immunochemiluminescent assay (ICMA), Scantibodies’ Total Intact PTH™ IRMA, DiaSorin’s N-tact® iPTH IRMA, DPC’s Coat-A-Count® iPTH IRMA, Roche’s Elecsys® iPTH ICMA, and DSL’s Active® iPTH IRMA. Results: Method comparison showed considerable interassay differences in the measurement of iPTH in ESRD patients. IPTH values assessed by other methods ranged, on average, from 60% to 152% of the Nichols Allegro IRMA values. Of the 6 iPTH assays tested, only the Scantibodies Total Intact PT IRMA (P = 0.7554) and the Roche Elecsys iPTH ICMA (P = 0.1327) resulted in iPTH values not statistically different from those obtained with the Nichols Allegro iPTH IRMA. Conclusions: Noncomparability among iPTH assays remains a distinct problem for the management of ESRD patients. These results should be taken into consideration when determining the course of medical treatment based on measured iPTH concentrations

Sign in / Sign up

Export Citation Format

Share Document